Confessions of a Biotech Investor

Recently I purchased a small position in MannKind (MNKD) on a pullback, cost basis 10.03 a share. Seemingly went up everyday. Then, it fell off the cliff. A FDA request for additional information and it's interpretation tanked the stock. Down 24% in one day, it has continued to selloff. Currently down nearly 40% from my original buy point and it has no signs of slowing down. While I have no special insight into the workings of the FDA nor the drug, Affrezza, up for approval, I have to say that the market reaction is wrong in my opinion. I will double down if it falls to or below 5.50 a share.

I understand this is a very risky proposition, especially from a technical analysis standpoint. All I can say is I've got a very strong gut feeling that it gets approved with few if any hitches. I'm following my gut this time....

E-mail me when people leave their comments –

You need to be a member of StockBuz to add comments!

Join StockBuz

Comments

  •   Update:  After reading The Intelligent Investor and experiencing the epiphany that followed, I eventually sold out of my entire position in MNKD (at at least a 50% loss I might add) and deployed the money in equities that I could actually figure out a valuation on.   I still follow this company and I still think that it will succeed with Affrezza.  I will revisit it eventually through either the purchase of warrants(  http://www.otcmarkets.com/stock/MNKDW/news ) or through the use of long term options.  Either way I will risk considerably less with the potential to make at least my losses back if not that and considerably more.

  • In late January MNKD received a CRL from the FDA requesting additional trials with the new delivery system.  Price tanked. Was trading below $6. Today earnings were released accompanied by the conference call.  Financing will be dicey starting in the the fourth quarter and they have already laid people off to help save cash.  Price fell below $4 a share, I bought more at $3.83 a share today.  My feeling is it will either find a partner, be bought out, or taken private.  The prospects of Affrezza and especially the delivery system are to strong for the company to be allowed to fall in my opinion.  I will add to my position again if price fall below $3, especially if it approaches $2.  This approach is fraught with risk and I suggest others do not follow unless you too have balls of steel and a complete lack of functional brain cells!
  • http://seekingalpha.com/article/240665-clearing-up-the-uncertainty-... Couldn't have said it better myself.
  • PDUFA date of December 27 for Affrezza..... remember PDUFA dates are more like guidelines for approval decisions, delayed decisions not uncommon.
  • http://seekingalpha.com/article/206605-a-giant-leap-for-mannkind?so... Apparently I am not the only one that feels this way...
This reply was deleted.

We welcome you to post a blog entry, oped or share your daily reading with us as long as it is relevant to the topic of investing and not an attempt to sell a product, proprietary strategy, platform or other service. Please provide links to any research data and if re-posting other articles, give credit where credit is due providing a back link to the original site.

300 words minimum per post. You may also sort by category or search by topic. Don't forget to comment and please "share" via Facebook, Twitter and Google+. If you have any questions, please contact us.

FOLLOW STOCKBUZ

__________________

This is a member-supported site. Please donate when you can to help pay the rent. Thank you!

Stay Informed. Sign up for the FREE StockBuz eNewsletter

________________

Investing involves substantial risk. All content is subject to StockBuz disclaimer.

Create Income With Option Spreads

All content on StockBuz.net is subject to disclaimer and Terms of Service